Zhang Taotao, Liu Peiqian
Department of Endocrinology, Fengyang People's Hospital, Fengyang, China.
Prev Med Rep. 2025 May 5;54:103101. doi: 10.1016/j.pmedr.2025.103101. eCollection 2025 Jun.
The relationship between the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and mortality in patients with diabetes/prediabetes remains uncertain. This study aimed to evaluate linear and non-linear associations between the HALP score and all-cause and cardiovascular mortality in this population and identify potential clinically relevant thresholds.
We analyzed data from 19,350 United States adults with diabetes/prediabetes using two linked datasets: the National Health and Nutrition Examination Survey (NHANES, 2005-2018) and mortality records from the National Death Index (NDI), with follow-up through December 31, 2019. Kaplan-Meier survival curves, Cox proportional hazards models, and restricted cubic splines (RCS) were used to evaluate the HALP score and mortality associations.
Kaplan-Meier analysis revealed the highest all-cause mortality in Q1, the lowest all-cause mortality in Q3, and the lowest cardiovascular mortality in Q4 (-value <0.0001). Cox regression analysis demonstrated significantly reduced risks of all-cause mortality (HR 0.64, 95 % CI 0.58, 0.73) and cardiovascular mortality (HR 0.58, 95 % CI 0.42, 0.82) in Q4 compared to Q1. RCS identified an L-shaped association between the HALP score and mortality, with inflection points at 42.29 (all-cause) and 39.98 (cardiovascular).
An L-shaped association between the HALP score and both all-cause and cardiovascular mortality in participants with diabetes mellitus or prediabetes.
血红蛋白、白蛋白、淋巴细胞和血小板(HALP)评分与糖尿病/糖尿病前期患者死亡率之间的关系仍不明确。本研究旨在评估该人群中HALP评分与全因死亡率和心血管死亡率之间的线性和非线性关联,并确定潜在的临床相关阈值。
我们使用两个关联数据集分析了19350名美国糖尿病/糖尿病前期成年人的数据:国家健康与营养检查调查(NHANES,2005 - 2018年)和国家死亡指数(NDI)的死亡率记录,随访至2019年12月31日。采用Kaplan-Meier生存曲线、Cox比例风险模型和受限立方样条(RCS)来评估HALP评分与死亡率的关联。
Kaplan-Meier分析显示,第一四分位数(Q1)的全因死亡率最高,第三四分位数(Q3)的全因死亡率最低,第四四分位数(Q4)的心血管死亡率最低(P值<0.0001)。Cox回归分析表明,与Q1相比,Q4的全因死亡率(风险比[HR] 0.64,95%置信区间[CI] 0.58,0.73)和心血管死亡率(HR 0.58,95% CI 0.42,0.82)显著降低。RCS确定HALP评分与死亡率之间呈L形关联,全因死亡率的拐点为42.29,心血管死亡率的拐点为39.98。
糖尿病或糖尿病前期参与者的HALP评分与全因死亡率和心血管死亡率之间呈L形关联。